Tesamorelin Dosage and Benefits for Visceral Belly Fat

Tesamorelin is a synthetic growth hormone releasing hormone (GHRH) analog studied for its effect on visceral adipose tissue (VAT), the deep belly fat packed around the organs. It works by nudging the pituitary to release the body's own growth hormone in natural pulses, rather than adding growth hormone directly.

The standout finding across clinical literature is selectivity. Studies report roughly a 15 to 20 percent reduction in visceral fat over 26 weeks, with little change to subcutaneous fat, the pinchable layer just under the skin. That distinction shapes why people research it and how the dose is framed. Tesamorelin is a research compound and is not approved for general human use. Nothing here is dosing advice. Talk to a licensed clinician before making any decision.

The standard reference dose

Clinical studies of tesamorelin (sold under the brand Egrifta for a specific approved indication) used a single fixed dose, which is why the number is unusually consistent in the literature.

• Reference dose: 2 mg, given once daily by subcutaneous injection
• Timing in studies: typically dosed in the evening, to mirror the body's natural overnight growth hormone pulse
• Study length: benefits on VAT were measured at 26 weeks, with maintenance often studied out to 52 weeks
• Form: supplied as a lyophilized (freeze dried) powder that must be reconstituted before use

Unlike GLP-1 peptides, tesamorelin protocols in the literature do not use a slow titration ladder. The studied dose was the same 2 mg from day one. Vials are commonly sold as 5 mg or 10 mg of total powder, so one vial holds several days of the 2 mg reference dose.

Reconstitution and the dosing math

Because the powder comes in different vial sizes, the volume you draw for a 2 mg dose depends entirely on how much bacteriostatic water you add. Run the numbers with the reconstitution calculator before you draw anything. Here is a worked example on a 10 mg vial.

• Vial: 10 mg tesamorelin powder
• Add: 2 mL bacteriostatic water
• Concentration: 10 mg divided by 2 mL = 5 mg/mL
• Target dose: 2 mg
• Volume to draw: 2 mg divided by 5 mg/mL = 0.4 mL
• On a U-100 insulin syringe, 0.4 mL = 40 units

Change the water and the unit count changes. Add 1 mL to the same 10 mg vial and the concentration becomes 10 mg/mL, so a 2 mg dose is 0.2 mL, or 20 units. The milligram amount is fixed by the protocol; the units on the syringe are just a function of your mix. If unit conversions trip you up, the mg to units calculator maps milligrams to syringe marks for any concentration.

Why it targets visceral fat, not pinchable fat

Visceral fat sits deep in the abdominal cavity and is more metabolically active than the subcutaneous layer. Growth hormone signaling preferentially mobilizes this deep fat. Because tesamorelin raises the body's own pulsatile growth hormone rather than flooding the system, studies saw VAT drop while subcutaneous fat and body weight stayed relatively flat. This is not a general weight loss profile and not a fat-anywhere effect. People comparing fat-loss mechanisms often look at GLP-1 options like tirzepatide and semaglutide, which work through appetite and a different pathway entirely.

Storage and handling

Tesamorelin is a fragile peptide. Handling in the literature is consistent with other reconstituted peptides.

• Keep the sealed powder refrigerated until use
• Reconstitute gently by swirling, never shaking, to avoid shearing the peptide
• Store the mixed vial in the refrigerator and use within the window your source specifies
• Inspect for cloudiness or particles before drawing

For deeper handling detail, see the guides on how long reconstituted peptides last and whether peptides need refrigeration. To compare tesamorelin against other GHRH and GH-axis compounds, browse the full peptide reference library.

Bottom line

The tesamorelin reference dose in clinical research is a flat 2 mg once daily, with no titration ladder. Its defining trait is selectivity for visceral fat, around 15 to 20 percent over 26 weeks, with minimal effect on the subcutaneous layer. The actual syringe units depend on your reconstitution math, not the protocol. Keep all dosing decisions with a licensed clinician and read the full disclaimer.